New Data From Head-To-Head Study Confirms Once-Daily Levemir(R) Is As Effective As Glargine Over A 24-hour Period In Subjects With Type 2 Diabetes

A head-to-head study announced at the American Diabetes Association (ADA) meeting demonstrated that Levemir® (insulin detemir [rDNA origin] injection) can be used once daily and had a comparable blood glucose response to insulin glargine over a 24-hour period in patients with type 2 diabetes.

More: continued here

Filed under: Clinical Trials on June 10th, 2008